Funding
Phico Therapeutics Ltd, which is developing treatments for drug-resistant superbugs, has raised £1.8 million from institutional investors and business angels, bringing the amount the Cambridge-based company has raised in the past year to £3.7 million.
Phico’s SASPject technology works by inactivating the DNA of targeted bacteria. The first product against antibiotic-resistant Staphylococcus aureus is in clinical trials. The new money will be used to support the clinical development programme and will also fund the continuing development of the SASPject platform to treat other infections.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
